Dynavax should take a leaf from its vaccine maker peer, Novavax, and work to monetize its CpG1018 adjuvant. Learn more about ...

The U.S. Food and Drug Administration has approved a new non-opioid pain medication developed by Boston-based Vertex ...

Faced with the encroaching threats of patent expirations and generics, biopharma companies in 2024 invested 33% more in ...

Novavax (NVAX) closed the most recent trading day at $8.45, moving +0.24% from the previous trading session. The stock trailed the S&P 500, which registered a daily gain of 0.72%. Meanwhile, the Dow ...

Novavax (NVAX) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

Shares of Novavax Inc. NVAX slipped 2.99% to $8.43 Monday, on what proved to be an all-around dismal trading session for the stock market, with the NASDAQ Composite Index COMP falling 1.20% to ...

Check the time stamp on this data. Updated AI-Generated Signals for Novavax Inc. (NVAX) available here: NVAX. Type a few ...

Capstone Companies, Inc. (OTCQB: CAPC) announced today the appointment of Brian Rosen as a non-employee director, effective January 20, 2025.

SINGAPORE: The updated JN.1 Novavax/Nuvaxovid COVID-19 vaccine will be offered under the national vaccination programme at ...

Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced progress in Q4 2024 advancing its corporate growth strategy through its ...

Novavax (NVAX) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term.